Scarica l'app Stockscreener
0.6884
5.58%
-0.0407
Dopo l'orario di chiusura:
.69
0.0016
+0.23%
Precedente Chiudi:
$0.7291
Aprire:
$0.7049
Volume 24 ore:
666.24K
Relative Volume:
0.63
Capitalizzazione di mercato:
$22.91M
Reddito:
-
Utile/perdita netta:
$-55.73M
Rapporto P/E:
-0.2133
EPS:
-3.2274
Flusso di cassa netto:
$-68.87M
1 W Prestazione:
-22.21%
1M Prestazione:
+40.32%
6M Prestazione:
-56.15%
1 anno Prestazione:
-78.01%
Intervallo 1D:
$0.681
$0.7397
Intervallo di 1 settimana:
$0.681
$0.8849
Portata 52W:
$0.3151
$3.25
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.6884 | 22.91M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Ripresa | UBS | Neutral |
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR - TradingView
JSPR|Jasper Therapeutics Inc|Price:0.689|Chg%:-0.041 - TradingKey
Jasper Therapeutics Market Sentiment - Benzinga España
Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement - Bitget
Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com - Investing.com Canada
Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares - Stock Titan
Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal - Stock Titan
Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes - Stock Titan
Form 4 Jasper Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement - Bitget
Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options - Stock Titan
Jasper Therapeutics (JSPR) director details common and preferred stake - Stock Titan
Jasper closes Kira deal, extends cash runway - MSN
Jasper Therapeutics (JSPR) holders outline 3,349,547-share stake after Kira deal - Stock Titan
Jasper Therapeutics stock trades sideways as cash position and clinical pipeline shape outlook - AD HOC NEWS
Jasper Closes Kira Deal, Extends Cash Runway - Benzinga
Jasper gets a lifeline in merger with immune drugmaker Kira - BioPharma Dive
Jasper completes Kira merger, lines up $132 million financing - The Pharma Letter
Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026 - marketscreener.com
Jasper Therapeutics Completes Kira Acquisition and PIPE Financing - TipRanks
Patrick Crutcher appointed to Jasper Therapeutics board; Matthew Ros named COO - TradingView
Jasper Therapeutics (NASDAQ: JSPR) buys Kira, adds $132M PIPE cash - Stock Titan
Jasper Therapeutics acquires Kira, extends cash runway - TipRanks
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m - Investing.com UK
Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy - Bitget
$Jasper Therapeutics (JSPR.US)$ - Moomoo
Jasper Therapeutics acquires Kira Pharmaceuticals for $132m By Investing.com - Investing.com Nigeria
Jasper Therapeutics: Jeet Mahal to Be Pres and CEO of Combined Co - Moomoo
Jasper Therapeutics Merges With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics merges with Kira Pharmaceuticals, raising $132M to advance immunology drug pipeline. - Pluang
Jasper Therapeutics: Combined Co Will Focus on Advancing Consolidated Pipeline of Potential Best-In-Class Innovative Therapies for Immunologically-Driven Disorders >JSPR - Moomoo
Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028 - TradingView
Jasper Therapeutics (NASDAQ: JSPR) closes Kira merger and $132M preferred financing - Stock Titan
Press Release: Jasper Therapeutics Announces Merger With Kira Pharmaceuticals - Moomoo
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal - Bitget
Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake - Stock Titan
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Stock Rebounds 6.83% as Biotech Sentiment ImprovesPCR Extreme - dars.gov.et
Jasper Therapeutics stock holds the focus. Company profile stays central. - Ad-hoc-news.de
Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Stock Analysis Report | Financials & Insights - Benzinga España
Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
Price to book forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
JSPRJasper Therapeutics Inc Options - Finviz
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):